4//SEC Filing
Tarriff Scott 4
Accession 0000950170-24-023198
CIK 0000827871other
Filed
Feb 28, 7:00 PM ET
Accepted
Feb 29, 4:44 PM ET
Size
7.7 KB
Accession
0000950170-24-023198
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Tax Payment
Common Stock
2024-02-27$6.44/sh−3,154$20,312→ 462,740 total - Award
Common Stock
2024-02-27+12,950→ 465,894 total
Holdings
- 992,623(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Represents shares of Common Stock received upon vesting of performance stock units ("PSUs") that were granted on February 2, 2021.
- [F2]Reflects the transfer of 88,181 shares of Common Stock pursuant to a Rule 16a-12 transaction.
- [F3]The disposition reported on this Form 4 represents shares of Common Stock withheld by the Issuer to cover the tax liability upon the vesting of PSUs on February 27, 2024 and does not represent a discretionary transaction by the Reporting Person.
- [F4]Shares held by the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust") for the benefit of the Reporting Person's spouse and children. The Reporting Person does not have investment control over the shares held by the Trust and disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest, if any, therein.
Documents
Issuer
EAGLE PHARMACEUTICALS, INC.
CIK 0000827871
Entity typeother
Related Parties
1- filerCIK 0001469124
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Feb 29, 4:44 PM ET
- Size
- 7.7 KB